The State Of Biotech M&A In 2023
Source: Life Science Leader
By Kim Spoerri and Jess Cymbaluk
Beset by economic uncertainty resulting from continued inflation, increasing interest rates, supply chain disruptions, and the conflict in Ukraine, the dollar value of global M&A activity in 2022 was down 37% from 2021’s record high. The biotech sector was no exception to the overall M&A market’s year-over-year decline, with 2022 aggregate deals’ value down by 41% to $158.5 billion and deals’ volume down by 30% to 258 deals.
VIEW THE MAGAZINE ARTICLE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader X
Subscribe to Life Science Leader